Summary Seven consecutive patients with intra-abdominal desmoplastic small round-cell tumours were screened at presentation for carcinoembryonic antigen (CEA), Ca19-9, Cal5-3, Ca125, alpha-fetoprotein (AFP), human chorionic gonadotrophin (hCG) and neuronspecific enolase (NSE). Initially elevated tumour markers were used to monitor therapy and follow-up. Tumour marker assays were all in the normal range, with the exception of Cal 25 and NSE. The Cal 25 level was initially high in six of the seven patients (86%) with a median value of 200 U ml-' and a range of 22-735 U ml-'. The NSE value was elevated before therapy in three of the five patients (60%) for whom assay results were available, with a median of 19 ng ml-' and a range of 6.8-37.5 ng ml'. Cal 25 normalized in five out of six cases and NSE always normalized during chemotherapy, but neither of these two tumour markers correlated specifically with response, as only one patient experienced a partial response, five tumour stabilization and the remaining patient tumour progression. At progression, Cal 25 was again elevated in two out of four cases several weeks before clinical relapse and NSE in only one out of three cases. Cal 25 and NSE are frequently raised in the serum of patients with intra-abdominal desmoplastic small round-cell tumours before therapy, but are not reliable monitors of the course of the disease. However, normalization is frequently associated with an improvement of symptoms or a moderate clinical response.
Intra-abdominal small round-cell tumour is a recently recognized clinicopathological entity (Gerald et al, 1989; Ord6nez et al, 1989) . This rare neoplasm occurs predominantly in children and young adults and is histologically distinct from other small round-cell tumours because of its immunohistochemical pattern and the presence of an abundant desmoplastic stroma (Gerald et al, 1993) . Divergent differentiation is commonly assessed by immunohistochemical staining for epithelial (keratin, epithelial membrane antigen), neural (neuron-specific enolase) and muscular (desmin) markers (Gerald et al, 1991; Ord6fiez et al, 1993) . A reciprocal translocation t (11; 22) (pl3; q12) is specific to this entity and is responsible for fusion -of the EWS and WT1 genes (Ladanyi et al, 1991) . This malignancy is hardly chemosensitive and the prognosis is usually unfavourable, although several cases of partial or complete response to therapy with long-term survival have been reported (Gerald et al, 1991; Farhat et al, 1995) . Despite the wellrecognized histologically divergent differentiation of this tumour, no data exist in the literature concerning serum tumour markers in these patients. In this study, we investigated multiple tumour marker assays before treatment to determine the relevance of initially elevated tumour markers for monitoring the course of the disease.
PATIENTS AND METHODS
Between November 1991 and November 1994, seven patients were diagnosed as having intra-abdominal small round-cell staining for Cal 25 was not performed. Patients always presented with a pelvic or abdominal primary involving the peritoneum.
Distant metastases were present in five cases, the liver being the affected site in three and retroperitoneal lymph nodes in two. Tumour burden was high in all cases. Surgical debulking was performed initially in three patients, but measurable residual tumour persisted in all cases. Chemotherapy was initiated in these three patients and the four others and consisted of a combination of doxorubicin, cisplatin, etoposide and cyclophosphamide (PAVEP regimen) (Arriagada et al, 1993) . Tumour response was assessed every two cycles by pelvic and abdominal computerized tomography (CT) scan.
Serum carcinoembryonic antigen (CEA), Cal9-9, Cal5-3, Cal25, human chorionic gonadotrophin (hCG), alpha-fetoprotein (AFP) and NSE were measured at presentation in our institution (following debulking in three patients). Tumour markers were not measured in ascitic fluid.
CEA, Cal9-9, Cal25 and AFP were measured using the enzyme-linked immunosorbent assay (ELISA)/one-step sandwich assay. Ca15-3 was measured using the ELISA/two-step sandwich assay. A radioimmunoassay was used to measure hCG and NSE.
The upper thresholds considered normal for markers were 7 ng ml-' for CEA, 35 U ml-' for Cal9-9, 30 Ul 1-' for Cal5-3, 35 Ut 1-' for Cal25, 10 MUI 1-' for hCG, 10 ng ml-' for AFP and 12.5 ng ml-' for NSE. Changes in initially elevated serum tumour markers were examined during the clinical course of the disease. Determinations were obtained monthly during chemotherapy and follow-up. RESULTS (Table 1) CEA, Cal9-9, Cal5-3, AFP and HCG values measured at presentation were always normal. Serum Ca125 was elevated in six out of seven cases (86%) with a mean of 270 U ml-' and a median of 200 U ml-' (range 22-735 U ml-'). Serum NSE was obtained in five cases before therapy and was elevated in three (60%). The mean value was 19 ng ml-' and median was 19.5 ng ml-' (range 6.8-37.5 ng ml-'). During chemotherapy, disease assessment showed one partial response (PR), five cases of stable disease (SD) including two minor responses, defined as a volume reduction of < 50% (MR), and one case of progressive disease (PD). The clinical outcome of four of these seven patients has been reported previously (Farhat et al, 1995) . Despite this apparent poor response rate, chemotherapy frequently obtained a significant although non-measurable reduction of ascitic effusions. Initially elevated Cal25 normalized in five out of six cases, but did not correlate specifically with clinical response: one PR and four SD including two MR. However, all these five patients experienced a parallel decrease in their ascitic effusions. The sole case with a persistently elevated Cal25 level was a patient with stable disease. The patient with an initially normal Cal 25 level experienced progressive disease, with tumour markers (Cal25 and NSE) always in the normal range during follow-up.
The NSE value normalized during therapy in all three cases in whom it was raised initially. These patients achieved an MR in one case and SD was noted in two cases.
At progression, the Cal25 assay was performed in four cases, and the value had increased in two (50%), several weeks before clinical relapse. Ca125 never normalized in one of these two patients. NSE was measured concomitantly in three cases and became elevated at progression in one (33%).
DISCUSSION
Intra-abdominal small round-cell tumours are very rare malignancies and only a few authors have reported series of more than five patients (Gerald et al, 1991; Varma et al, 1992; Ordofiez et al, 1993; Frappaz et al, 1994; Farhat et al, 1995) . Here, we report our experience of multiple tumour marker screening in seven patients. To our knowledge, such a study has not been reported previously in the literature.
Our study shows that only two tumour markers are elevated before therapy in the serum of patients with intra-abdominal small round-cell tumours, Cal25 and NSE. Cal25 is an antigen determinant recognized by the monoclonal antibody, 0C125, that has been shown to provide useful information during the follow-up of ovarian carcinomas (Bast et al, 1983; Fisken et al, 1993) . However, this tumour marker is not specific for ovarian carcinomas and has been shown frequently to be raised in cases of ascitic and pleural effusions, benign tumours or other malignancies, particularly advanced non-small-cell lung cancer (Bergman et al, 1987; Diez et al, 1991) . The fact that ascites are frequently found in patients with intra-abdominal small round-cell tumours could explain why a high proportion of these patients have an elevated serum CaI25. Moreover, the frequent regression of ascites in our patients who received chemotherapy, and who were practically all affected by this disorder, probably accounts for the high incidence of Ca125 normalization, unless they were nonresponders. Immunostaining for Ca125 was not performed in our study. Investigators from the MD Anderson Cancer Center found a positive staining in only one of the five cases tested for Cal25 (Ordoniez et al, 1993) .
NSE was elevated in three out of five cases before therapy. NSE is a glycolytic enzyme that has been shown to be a sensitive tumour marker in a number of malignancies and especially in small-cell lung cancer, neuroblastoma and neuroendocrine tumours (Carney et al, 1982; Pring et al, 1982; Zeltzer et al, 1983) . Strong cellular staining for NSE has already been reported in neoplastic tissue samples by patients with intra-abdominal small round-cell tumours using immunohistochemical techniques (Gonzalez-Crussi et al, 1990; Gerald et al, 1991; Variend et al, 1991; Ord6oez et al, 1993; Frappaz et al, 1994; Farhat et al, 1995) . In the largest study by Ordoniez et al (1993) six of 12 tumour samples reacted for NSE. In the study by Gerald et al (1991) , in which an immunohistochemical analysis of NSE was available for eight patients, half of the cases had positive staining. This seems to be consistent with the three out of five patients with raised serum NSE levels in our study.
During therapy, serum NSE levels did not seem to correlate specifically with clinical response. However, if we assume that the neuroendocrine component of intra-abdominal desmoplastic small round-cell tumours is likely to be sensitive to chemotherapy, then this would account for the normalization of serum NSE. Thus, the lack of clinical response observed here is probably caused by other drug-resistant tumour components or to the abundant desmoplastic stroma.
At progression, serum Ca125 was raised again in half the patients and NSE in one of three cases. The limited value of serial NSE measurements in predicting relapse has been underscored recently in patients with small-cell lung cancer (Nou et al, 1990; Johnson et al, 1993; Van Zandwijk et al, 1990) . Our experience of serum NSE in monitoring progression confirms these data in intra-abdominal small round-cell tumours. However, further investigation with a larger series is needed to validate these data definitively.
